SCHEMBL1630672

SCHEMBL1630672

COc1ccc(S(=O)(=O)N(CC(=O)N2CCCC2c2ccc(F)cc2)c2cccc(Cl)c2)cc1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.48
NPSR1 Q6W5P4 3/20 0.48
KMT2A Q03164 3/20 0.48
MAPK1 P28482 2/20 0.48
MEN1 O00255 2/20 0.48
USP2 O75604 1/20 0.48
LMNA P02545 2/20 0.48
CRHBP P24387 1/20 0.47
CRHR2 Q13324 1/20 0.47
MAPT P10636 6/20 0.47
HTT P42858 2/20 0.47
KEAP1 Q14145 2/20 0.45
NFE2L2 Q16236 2/20 0.45
OXTR P30559 2/20 0.43
AVPR1A P37288 2/20 0.43
PKM P14618 1/20 0.43
GAA P10253 1/20 0.42
RORC P51449 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1630075 0.93 NPSR1 (0.52) ALDH1A1NPSR1KMT2AMAPK1MEN1
SCHEMBL1630074 0.93 MAPT (0.49) ALDH1A1NPSR1KMT2AMAPK1MEN1
SCHEMBL1630069 0.93 KMT2A (0.54) ALDH1A1NPSR1KMT2AMAPK1MEN1
SCHEMBL3425877 0.92 CRHBP (0.49) ALDH1A1NPSR1KMT2AMAPK1MEN1
SCHEMBL1629094 0.90 CRHBP (0.52) ALDH1A1NPSR1KMT2AMAPK1MEN1
SCHEMBL3428093 0.89 CRHBP (0.49) ALDH1A1NPSR1KMT2AMAPK1MEN1
SCHEMBL3423315 0.89 KEAP1 (0.51) ALDH1A1NPSR1KMT2AMAPK1MEN1
SCHEMBL1629490 0.89 KEAP1 (0.51) ALDH1A1NPSR1KMT2AMAPK1MEN1
SCHEMBL1630032 0.89 KEAP1 (0.51) ALDH1A1NPSR1KMT2AMAPK1MEN1
SCHEMBL1630103 0.89 ALDH1A1 (0.52) ALDH1A1NPSR1KMT2AMAPK1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2245006-B1 SULFONAMIDES AS OREXIN ANTAGONISTS HOFFMANN LA ROCHE (CH) 2011-06-01 EP disclosed
US-7932269-B2 Sulfonamides as orexin antagonists HOFFMANN-LA ROCHE INC. (US) 2011-04-26 US disclosed
US-7932269-B2 Sulfonamides as orexin antagonists HOFFMANN-LA ROCHE INC. (US) 2011-04-26 US disclosed
US-7932269-B2 Sulfonamides as orexin antagonists HOFFMANN-LA ROCHE INC. (US) 2011-04-26 US disclosed
US-20090186920-A1 SULFONAMIDES AS OREXIN ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-07-23 US disclosed
US-20090186920-A1 SULFONAMIDES AS OREXIN ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-07-23 US disclosed
US-20090186920-A1 SULFONAMIDES AS OREXIN ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-07-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186920-A1 SULFONAMIDES AS OREXIN ANTAGONISTS HCRTR2, HCRTR1, NPSR1 ALDH1A1 2403/4885NPSR1 3/4885KMT2A 934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.